Search

everythinglearnresearchcommunity

for

Search:↓

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Prostate size varies by ethnic group, age, residence, and blood glucose, but not by body measurements or fat.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Finasteride effectively treats baldness but may cause sexual side effects.

5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.

There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.

Certain drugs that block specific enzymes can help treat prostate diseases.

Wnt signaling is important for development and cell regulation but can cause diseases like cancer when not working properly.

Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

The conclusion is that androgenetic alopecia and senescent alopecia have unique gene changes, suggesting different causes and potential treatments for these hair loss types.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Mutations in certain receptors can cause diseases and offer new treatment options.

Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Testosterone conversion to 5α-DHT may not be essential for its effects on the skin.

Genomic approach finds new possible treatments for hair loss.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

DKK-1 gene linked to hair loss in AGA and AA patients; more research needed for potential therapy.

Increased PPARGC1α relates to hair thinning in common baldness.

Pumpkin seeds may improve health due to their rich nutrients and potential to treat various conditions.

Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.